PDL BioPharma

{{Infobox company |

| name = PDL BioPharma

| logo =

| type = Public

| traded_as = {{NASDAQ|PDLI}}
Russell 2000 Component

| foundation =

| location =

| key_people =

John McLaughlin (CEO)

Peter Garcia (CFO)

Cary Queen (Founder, former vice-president in charge of research)

Laurence J. Korn (Founder, former president)

| industry = Biotechnology

| products =

| revenue = $590.4 million (2015){{cite web|url=http://investor.pdl.com/releasedetail.cfm?ReleaseID=956199|title=PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results (NASDAQ:PDLI)|publisher=}}

| operating_income =

| net_income =

| assets =

| equity =

| num_employees =

| homepage = {{URL|http://pdl.com/}}

}}

PDL BioPharma (known as Protein Design Labs prior to 2006) is a publicly traded American holding company that since 2008 manages patents and other intellectual property that had been generated by the company.[https://web.archive.org/web/20160809081509/http://investing.businessweek.com/Research/stocks/snapshot/snapshot_article.asp?ticker=PDLI Bloomberg company profile] Page accessed May 31, 2016Peter Kolchinsky for In Vivo. July/August 2011 [http://www.racap.com/wp-content/uploads/2015/07/LastingPeace_IV1107_web-2.pdf How To Create A Lasting Peace Between Biotech Management, Shareholders And Employees] In 2008 in response to shareholder pressure, PDL spun out its active development programs to a company called Facet Biotech that it capitalized with $400 million.John Carroll for FierceBiotech. 2009 [http://www.fiercebiotech.com/special-report/emerging-drug-developer-facet-biotech Emerging Drug Developer: Facet Biotech][https://www.sec.gov/Archives/edgar/data/882104/000110465908078237/a08-30875_18k.htm PDL BioPharma, Inc. Form 8-K] December 17, 2008

Protein Design Labs, founded in 1986 by cell biologist Laurence J. Korn and mathematician Cary Queen,https://www.fool.com/investing/high-growth/2007/09/28/interview-with-pdl-co-founder-cary-queen aspx was a pioneer in humanizing monoclonal antibodies. Its humanization technology was used in several monoclonal antibody drugs under licensing and collaboration agreements; such products included trastuzumab (Herceptin), bevacizumab (Avastin), and palivizumab (Synagis).Thiel KA. A very firm handshake: biotech's growing negotiating power. Nat Biotechnol. 2005 Oct;23(10):1221-6. {{PMID|16211058}} It held its initial public offering in 1992Staff, New York Times. January 30, 1992 [https://www.nytimes.com/1992/01/30/business/finance-briefs-510792.html Finance Briefs] and by 1994 it had 13 compounds in its pipeline, and had partnered its lead product, the humanized monoclonal antibody daclizumab, with Roche under a license that called for a 15% royalty.The Pharma Letter. July 25, 1994 [http://www.thepharmaletter.com/article/protein-design-rising-star-in-a-depressed-sector Protein Design: Rising Star In A Depressed sector?] Daclizumab became the first humanized monoclonal antibody approved for human use in 1997.Lawrence M. Fisher for The New York Times. December 12, 1997 [https://www.nytimes.com/1997/12/12/us/genetically-engineered-drug-approved-for-kidney-transplants.html Genetically Engineered Drug Approved for Kidney Transplants] PDL made another public offering in 2000, at the peak of the biotech IPO window that ran from 1998 to 2001.Wiechers IR, Perin NC, Cook-Deegan R. The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, 1990 to 2004. Genome Med. 2013 Sep 20;5(9):83. {{PMID|24050173}} [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971346/pdf/gm487.pdf PMC 3971346] In 2003 it settled litigation with Genentech over royalty payments owed to PDL under their license agreement; annual royalties were anticipated at that time to be around $90M per year.Times Wire Services in the Los Angeles Times. December 02, 2003 [https://www.latimes.com/archives/la-xpm-2003-dec-02-fi-genentech2-story.html Genentech to Pay Royalties in Patent Dispute] These are the kinds of intellectual property and license agreements that PDL manages on behalf of its shareholders since 2008; in 2007 those royalty payments were around $220 million.

One of the development programs that PDL had transferred to Facet was the use of daclizumab in indications it had never licensed to Roche, including multiple sclerosis. Facet partnered that development program with Biogen Idec which attempted a hostile buy out of Facet for $350M in 2009;Luke Timmerman for Xconomy. September 4, 2009 [http://www.xconomy.com/boston/2009/09/04/biogen-idec-makes-hostile-350m-takeover-bid-for-facet-biotech/ Biogen Idec Makes Hostile $350M Takeover Bid for Facet Biotech] Facet rejected that offer and was purchased by Abbvie for $450 million in cash the next year.Staff, New York Times Dealbook. March 9, 2010. [https://dealbook.nytimes.com/2010/03/09/abbott-to-buy-facet-biotech-for-67-premium/ Abbott to Buy Facet Biotech for 67% Premium] The FDA approved daclizumab for multiple sclerosis in 2016 under the trade name Zinbryta.[https://web.archive.org/web/20160529120600/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504000.htm FDA News Release: FDA approves Zinbryta to treat multiple sclerosis] May 27, 2016

PDL Biopharma has filed for a liquidation under Delaware Law that was effective January 7 2021. The liquidation plan was approved by shareholders in October 2020.